About Galapagos N.V.
https://www.glpg.comGalapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.
CEO
Henry Gosebruch
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Leerink Partners
Outperform
RBC Capital
Sector Perform
Morgan Stanley
Underweight
Barclays
Underweight
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:16.71M
Value:$570.06M
TANG CAPITAL MANAGEMENT LLC
Shares:4.15M
Value:$141.64M
MADISON AVENUE PARTNERS, LP
Shares:2.2M
Value:$74.92M
Summary
Showing Top 3 of 116
About Galapagos N.V.
https://www.glpg.comGalapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $71.16M ▲ | $50.41M ▼ | $-202.11M ▼ | -284.02% ▼ | $-3.1 ▼ | $-189.53M ▼ |
| Q2-2025 | $65.29M ▼ | $117.61M ▼ | $-105.75M ▲ | -161.97% ▲ | $-1.61 ▲ | $-101.12M ▲ |
| Q1-2025 | $74.98M ▼ | $219.96M ▲ | $-153.4M ▼ | -204.6% ▼ | $-2.33 ▼ | $-158.71M ▼ |
| Q4-2024 | $75.5M ▲ | $25.29M ▼ | $25.31M ▲ | 33.52% ▲ | $0.29 ▲ | $-53.87M ▲ |
| Q3-2024 | $59.85M | $114.14M | $-50.43M | -84.26% | $-0.71 | $-152.76M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.58B ▲ | $4.13B ▲ | $1.25B ▲ | $2.88B ▲ |
| Q2-2025 | $3.09B ▼ | $3.82B ▼ | $1.17B ▼ | $2.64B ▼ |
| Q1-2025 | $3.3B ▲ | $4.02B ▼ | $1.27B ▲ | $2.75B ▼ |
| Q4-2024 | $3.12B ▼ | $4.14B ▼ | $1.24B ▼ | $2.9B ▲ |
| Q3-2024 | $3.34B | $4.17B | $1.31B | $2.86B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-202.11M ▼ | $-62.61M ▲ | $56.74M ▼ | $-1.26M ▼ | $-7.21M ▲ | $-65.46M ▲ |
| Q2-2025 | $-105.75M ▲ | $-108.78M ▼ | $74.71M ▼ | $-600K ▲ | $-36.4M ▼ | $-112.94M ▼ |
| Q1-2025 | $-153.4M ▼ | $-38.61M ▲ | $84.75M ▲ | $-1.01M ▲ | $43.83M ▲ | $-43.86M ▲ |
| Q4-2024 | $25.31M ▲ | $-59.37M ▲ | $68.36M ▲ | $-1.6M ▼ | $8.72M ▲ | $-64.79M ▲ |
| Q3-2024 | $-50.43M | $-71.79M | $56.56M | $-1.09M | $-16.8M | $-76.1M |
CEO
Henry Gosebruch
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Leerink Partners
Outperform
RBC Capital
Sector Perform
Morgan Stanley
Underweight
Barclays
Underweight
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:16.71M
Value:$570.06M
TANG CAPITAL MANAGEMENT LLC
Shares:4.15M
Value:$141.64M
MADISON AVENUE PARTNERS, LP
Shares:2.2M
Value:$74.92M
Summary
Showing Top 3 of 116